osilodrostat   Click here for help

GtoPdb Ligand ID: 8310

Synonyms: Isturisa® | LCI-699 | LCI699
Approved drug PDB Ligand
osilodrostat is an approved drug (EMA & FDA (2020))
Compound class: Synthetic organic
Comment: Osilodrostat was designed as an inhibitor of aldosterone synthase (CYP11B2), but is also reported to inhibit the closely related enzyme, 11-beta-hydroxylase (CYP11B1) and hence as an inhibitor of cortisol biosynthesis [8]. It is this latter action of osilodrostat that is harnessed for clinical utility in Cushing's disease. The drug is orally bioavailable.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 2
Hydrogen bond donors 0
Rotatable bonds 1
Topological polar surface area 41.61
Molecular weight 227.09
XLogP 2.18
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES N#Cc1ccc(c(c1)F)C1CCc2n1cnc2
Isomeric SMILES N#Cc1ccc(c(c1)F)[C@H]1CCc2n1cnc2
InChI InChI=1S/C13H10FN3/c14-12-5-9(6-15)1-3-11(12)13-4-2-10-7-16-8-17(10)13/h1,3,5,7-8,13H,2,4H2/t13-/m1/s1
InChI Key USUZGMWDZDXMDG-CYBMUJFWSA-N
References
1. Amar L, Azizi M, Menard J, Peyrard S, Watson C, Plouin PF. (2010)
Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism.
Hypertension, 56 (5): 831-8. [PMID:20837883]
2. Calhoun DA, White WB, Krum H, Guo W, Bermann G, Trapani A, Lefkowitz MP, Ménard J. (2011)
Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial.
Circulation, 124 (18): 1945-55. [PMID:21986283]
3. Daniel E, Newell-Price JD. (2015)
Therapy of endocrine disease: steroidogenesis enzyme inhibitors in Cushing's syndrome.
Eur J Endocrinol, 172 (6): R263-80. [PMID:25637072]
4. Duggan S. (2020)
Osilodrostat: First Approval.
Drugs, 80 (5): 495-500. [PMID:32141023]
5. Fleseriu M. (2015)
Medical Treatment of Cushing Disease: New Targets, New Hope.
Endocrinol Metab Clin North Am, 44 (1): 51-70. [PMID:25732642]
6. Fleseriu M, Petersenn S. (2015)
Medical therapy for Cushing's disease: adrenal steroidogenesis inhibitors and glucocorticoid receptor blockers.
Pituitary, 18 (2): 245-52. [PMID:25560275]
7. Wang HZ, Tian JB, Yang KH. (2015)
Efficacy and safety of LCI699 for hypertension: a meta-analysis of randomized controlled trials and systematic review.
Eur Rev Med Pharmacol Sci, 19 (2): 296-304. [PMID:25683946]
8. Yin L, Hu Q, Emmerich J, Lo MM, Metzger E, Ali A, Hartmann RW. (2014)
Novel pyridyl- or isoquinolinyl-substituted indolines and indoles as potent and selective aldosterone synthase inhibitors.
J Med Chem, 57 (12): 5179-89. [PMID:24899257]